Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial

Details

• Alternative Title:
  Vaccine
• Personal Author:
  Anand, Abhijeet ; Zaman, K. ; Estívariz, Concepción F. ; Yunus, Mohammad ; Gary, Howard E. ; Weldon, William C. ; Bari, Tajul I. ; Oberste, M. Steven ; Wassilak, Steven G. ; Luby, Stephen P. ; Heffelfinger, James D. ; Pallansch, Mark A.
  More +
• Description:
  Introduction: ; Inactivated poliovirus vaccine (IPV) introduction and phased oral poliovirus vaccine (OPV) cessation are essential for eradication of polio. ; Methods: ; Healthy 6-week old infants in Bangladesh were randomized to one of five study arms: receipt of trivalent OPV (tOPV) or bivalent OPV (bOPV) at ages 6, 10 and 14 weeks, intramuscular IPV or intradermal one-fifth fractional dose IPV (f-IPV) at ages 6 and 14 weeks, or f-IPV at ages 6 and 14 weeks with bOPV at age 10 weeks (f-IPV/bOPV). All participants received tOPV at age 18 weeks. ; Results: ; Of 975 infants randomized, 95% (922) completed follow-up. Type 1 seroconversion after 3 doses at 6, 10 and 14 weeks was higher with bOPV compared with tOPV (99% vs 94%, p = 0.019). Seroconversions to types 1 and 3 after 2 IPV doses at ages 6 and 14 weeks were no different than after 3 doses of tOPV or bOPV at ages 6, 10 and 14 weeks. A priming response, seroconversion 1 week after IPV at 14 weeks among those who did not seroconvert after IPV at 6 weeks, was observed against poliovirus types 1, 2 and 3 in 91%, 84% and 97%, respectively. Compared with IPV, f-IPV failed non-inferiority tests for seroconversion with 1 or 2 doses and priming after 1 dose. ; Discussion: ; The findings demonstrate considerable priming with IPV at age 6 weeks, comparable immunogenicity of tOPV and bOPV, and inferior immunogenicity of one-fifth f-IPV compared with IPV. If IPV induced priming at age 6 weeks is similar to that at age 14 weeks, IPV could be administered at a younger age and possibly with a higher coverage.
• Subjects:
  • Article
  • Oral polio vaccine
  • Inactivated polio vaccine
  • Priming
  • Polio immunogenicity
  • Antibodies, Viral
  • Bangladesh
  • Female
  • Humans
  • Immunization Schedule
  More +
• Source:
  Vaccine. 33(48):6816-6822
• Pubmed ID:
  26476367
• Pubmed Central ID:
  PMC10423714
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  33
• Issue:
  48
• Download URL:
  https://stacks.cdc.gov/view/cdc/132024/cdc_132024_DS1.pdf
• File Type:
  [PDF - 903.14 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:45c9fd189489094b7750a6bbf9ac2dd748a698bb15cae6b9eaa7807e06fe7290